Photodynamic Therapy for Other Uses

  • George MartinEmail author


Over the course of the last two decades, the scope of PDT has expanded to include a broad spectrum of neoplastic, inflammatory, and infectious cutaneous and noncutaneous diseases. Four drugs have been approved for these other uses: porfimer sodium, verteporfin, aminolevulinic acid, and methyl aminolevulinic acid.


Methylene Blue Cutaneous Leishmaniasis Porfimer Sodium Necrobiosis Lipoidica Diabeticorum Methyl Aminolevulinate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Morton CA, McKenna KE, Rhodes LE. Guidelines for topical photodynamic therapy: update. Br J Dermatol. 2008;159:1245–66.PubMedCrossRefGoogle Scholar
  2. 2.
    Marcus SL, McIntyre WR. Photodynamic therapy systems and applications. Expert Opin Emerg Drugs. 2002;7(2):318–31.CrossRefGoogle Scholar
  3. 3.
    Taub AF. Photodynamic therapy: other uses. Dermatol Clin. 2007;25:101–9.PubMedGoogle Scholar
  4. 4.
    Mark S. Nestor MD PhD (chair), a Michael H. Gold MD (co-chair), b Arielle N. B. Kauvar MD, c Amy F. Taub MD, d Roy G. Geronemus MD, c Eva C. Ritvo MD, e Dore J. Gilbert MD, f Mitchel P. Goldman MD, g Donald F. Richey MD h (Consensus Panel). The use of photodynamic therapy in dermatology: results of a consensus conference. J Drugs Dermatol. 2006;5(2):140–54.PubMedGoogle Scholar
  5. 5.
    Alexiades-Armenakas M. Aminolevulinic acid photodynamic therapy for actinic keratoses/actinic cheilitis/acne: vascular lasers. Dermatol Clin. 2007;25:25–33.PubMedCrossRefGoogle Scholar
  6. 6.
    Niedre MJ, Yu CS, Patterson MS, Wilson BC. Singlet oxygen luminescence as an in vivo photodynamic therapy dose metric: validation in normal mouse skin with topical produce singlet oxygen using 5-aminolaevulinic acid. Br J Cancer. 2005;92:298–304.PubMedGoogle Scholar
  7. 7.
    Fritsch C, Homey B, Stahl W, Lehmann P, Ruzicka T, Sies H. Preferential relative porphyrin enrichment in solar keratoses upon topical application of 6-aminolevulinic acid methylester. Photochem Photobiol. 1998;68(2):218–21.PubMedGoogle Scholar
  8. 8.
    Likier HM, Levine JG, Lightdale C. Photodynamic therapy for completely obstructing esophageal carcinoma. Gastrointest Endosc. 1991;37:75–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Locicero J, Metzdorff M, Almgren C. Photodynamic therapy in the palliation of late-stage obstructing nonsmall-cell lung cancer. Chest. 1990;98:97–100.PubMedCrossRefGoogle Scholar
  10. 10.
    Photofrin® (porfimer sodium). “package insert” that accompanies an FDA approved drug. It often contains relevant information that is not published in the public domain. Axcan Scandipharm, Inc.; 2000.Google Scholar
  11. 11.
    Strasswimmer J, Grande DJ. Do pulsed lasers produce an effective photodynamic therapy response? Lasers Surg Med. 2006;38:22–5.PubMedCrossRefGoogle Scholar
  12. 12.
    Daniel MD, Hill JS. A history of photodynamic therapy. Aust N Z J Surg. 1991;61:340–8.CrossRefGoogle Scholar
  13. 13.
    Hamblin MR, Hasan T. Photodynamic therapy: a new antimicrobial approach to infectious disease? Photochem Photobiol Sci. 2004;3(5):436–50.PubMedCrossRefGoogle Scholar
  14. 14.
    Demidova TN, Hamblin MR. Photodynamic therapy targeted to pathogens. Int J Immunopathol Pharmacol. 2004;17(3):245–54.PubMedGoogle Scholar
  15. 15.
    Jori G, Fabris C, Soncin M, Ferro S, Coppellotti O, Dei D, et al. Photodynamic therapy in the treatment of microbial infections: basic principles and perspective applications. Lasers Surg Med. 2006;38(5):468–81.PubMedCrossRefGoogle Scholar
  16. 16.
    Sharma M, Visai L, Bragheri F, Cristiani I, Gupta PK, Speziale P. Toluidine blue-mediated photodynamic effects on staphylococcal biofilms. Antimicrob Agents Chemother. 2008;52(1):299–305.PubMedCrossRefGoogle Scholar
  17. 17.
    Menezes S, Capella MA, Caldas LR. Photodynamic action of methylene blue: repair and mutation in Escherichia coli. J Photochem Photobiol B. 1990;5(3–4):505–17.PubMedCrossRefGoogle Scholar
  18. 18.
    Millson CE, Wilson M, MacRobert AJ, Bown SG Exvivo treatment of gastric Helicobacter infection by photodynamic therapy. J Photochem Photobiol. 1996;32(1–2):59–65.Google Scholar
  19. 19.
    Maisch T. Phototoxicity of a novel porphyrin photosensitizer against MRSA in an ex-vivo porcine skin model. In: Presented at the sixth annual euro-PDT meeting. Berne, Switzerland, March 31–April 1, 2006.Google Scholar
  20. 20.
    Wong TW, Wang YY, Sheu HM, Chuang YC Bactericidal effects of toluidine blue-mediated photodynamic action on Vibrio vulnificus. Antimicrob Agents Chemother. 2005;49(3):895–902.PubMedCrossRefGoogle Scholar
  21. 21.
    Lambrechts SA, Demidova TN, Aalders MC, Hasan T, Hamblin MR. Photodynamic therapy for Staphylococcus aureus infected burn wounds in mice. Photochem Photobiol Sci. 2005;4(7):503–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Bisland SK, Chien C, Wilson BC, Burch S. Pre-clinicalin vitro and in vivo studies to examine the potential use of photodynamic therapy in the treatment of osteomyelitis. Photochem Photobiol Sci. 2006;5(1):31–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Burns RE, Greer JE, Mikhail G, Livingood CS. The significance of coral-red fluorescence of the skin. Arch Dermatol. 1967;96:436–40.PubMedCrossRefGoogle Scholar
  24. 24.
    Darras-Vercambre S, Carpentier O, Vincent P, Bonnevalle A, Thomas P. Photodynamic action of red light for treatment of erythrasma: preliminary results. Photodermatol Photoimmunol Photomed. 2006;22:153–6.PubMedCrossRefGoogle Scholar
  25. 25.
    Clayton TH, Harrison PV. Photodynamic therapy for infected leg ulcers. Br J Dermatol. 2007;156:384–5.PubMedCrossRefGoogle Scholar
  26. 26.
    Zeina B, Greenman J, Purdell WM, Das B. Killing of cutaneous microbial species by photodynamic therapy. Br J Dermatol. 2001;144:274–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Ma Z, Lienhardt C. Toward an optimized therapy for tuberculosis? Drugs in clinical trials and in preclinical development. Clin Chest Med. 2009;30(4):755–68, ix.Google Scholar
  28. 28.
    O’Riordan K, Akilov OE, Chang SK, Foley JW, Hasan T. Real-time fluorescence monitoring of ­phenothiazinium photosensitizers and their ­anti-­mycobacterial photodynamic activity against Mycobacterium bovis BCG in in vitro and in vivo models of localized infection. Photochem Photobiol Sci. 2007;6(10):1117–23.PubMedCrossRefGoogle Scholar
  29. 29.
    Wiegell SR, Kongshoj B, Wulf HC. Mycobacterium marinum infection cured by photodynamic therapy. Arch Dermatol. 2006;142:1241–2.PubMedCrossRefGoogle Scholar
  30. 30.
    Aubry A, Chosidow O, Caumes E, et al. Sixty-three cases of Mycobacterium marinum infection: clinical features, treatment, and antibiotic susceptibility of causative isolates. Arch Intern Med. 2002;162:1746–52.PubMedCrossRefGoogle Scholar
  31. 31.
    Calzavara-Pinton PG, Venturini M, Sala R. A comprehensive overview of photodynamic therapy in the treatment of superficial fungal infections of the skin. J Photochem Photobiol B. 2005;78(1):1–6.PubMedCrossRefGoogle Scholar
  32. 32.
    Bertoloni G, Zambotto F, Conventi L, Reddi E, Jori G. Role of specific cellular targets in the hematoporphyrin-sensitized photoinactivation of microbial cells. Photochem Photobiol. 1987;46:695–8.PubMedCrossRefGoogle Scholar
  33. 33.
    Ito T. Toluidine blue: the mode of photodynamic action in yeast cells. Photochem Photobiol. 1977;25:47–53.PubMedCrossRefGoogle Scholar
  34. 34.
    Zeina B, Greenman J, Corry D, Purcell WM. Cytotoxic effects of antimicrobial photodynamic therapy on keratinocytes in vitro. Br J Dermatol. 2002;146:568–73.PubMedCrossRefGoogle Scholar
  35. 35.
    Greenman J, Corry D, Purcell WM. Antimicrobial photodynamic therapy: assessment of genotoxic effects on keratinocytes in vitro. Br J Dermatol. 2003;148:229–32.PubMedCrossRefGoogle Scholar
  36. 36.
    Chabrier-Roselló Y, Foster TH, Pérez-Nazario N, Mitra S, Haidaris CG. Sensitivity of Candida albicans germ tubes and biofilms to photofrin-mediated phototoxicity. Antimicrob Agents Chemother. 2005;49(10):4288–95.PubMedCrossRefGoogle Scholar
  37. 37.
    Teichert MC, Jones JW, Usacheva MN, Biel MA. Treatment of oral candidiasis with methylene blue-mediated photodynamic therapy in an immunodeficient murine model. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002;93:155–60.PubMedCrossRefGoogle Scholar
  38. 38.
    Fuchs BB, Tegos GP, Hamblin MR, Mylonakis E. Susceptibility of Cryptococcus neoformans to photodynamic inactivation is associated with cell wall integrity. Int J Artif Organs. 2009;32(9):574–83.Google Scholar
  39. 39.
    Romagnoli C, Mares D, Sacchetti G, Bruni A. The photodynamic effect of 5-(4-hydroxy-1-butinyl)-2, 2-bithienyl on dermatophytes. Mycol Res. 1998;102:1519–24.CrossRefGoogle Scholar
  40. 40.
    Kamp H, Tietz HJ, Lutz M, Piazena H, Sowyrda P, Lademann J, Blume-Peytavi U. Antifungal effect of 5-aminolevulinic acid PDT in Trichophyton rubrum. Mycoses. 2005;48(2):101–7.PubMedCrossRefGoogle Scholar
  41. 41.
    Smijs TG, Mulder AA, Pavel S, Onderwater JJ, Koerten HK, Bouwstra JA. Morphological changes of the dermatophytes Trichophyton rubrum, after photodynamic treatment: a scanning electron microscopy study. Med Mycol. 2008;46:315–25.PubMedCrossRefGoogle Scholar
  42. 42.
    Kamp H, Tietz HJ, Lutz M, Piazena H, Sowyrda P, Lademann J, et al. Antifungal effect of 5-aminolevulinic acid PDT in Trichophyton rubrum. Mycoses. 2005;48:101–7.PubMedCrossRefGoogle Scholar
  43. 43.
    Watanabe D, Kawamura C, Masuda Y, Akita Y, Tamada Y, Matsumoto Y, et al. Successful treatment of toenail onychomycosis with photodynamic therapy. Arch Dermatol. 2008;144:19–21.PubMedCrossRefGoogle Scholar
  44. 44.
    Piraccini BM, Rech G, Tosti A. Photodynamic therapy of onychomycosis caused by Trichophyton rubrum. J Am Acad Dermatol. 2008;59:S75–6.PubMedCrossRefGoogle Scholar
  45. 45.
    Kosaka S, Akilov OE, O’Riordan K, Hasan T. A mechanistic study of delta-aminolevulinic acid-based photodynamic therapy for cutaneous leishmaniasis. J Invest Dermatol. 2007;127:1546–9.PubMedCrossRefGoogle Scholar
  46. 46.
    Abok K, Cadelas E, Brunk U. An experimental model system for leishmaniasis. Effects of porphyrin-compounds and menadione on leishmania parasites engulfed by cultured macrophages. APMIS. 1998;96:543–51.CrossRefGoogle Scholar
  47. 47.
    Reed RJ, Leone P. Porokeratosis – a mutant clone keratosis of the epidermis. Arch Dermatol. 1970;101:340–3.PubMedCrossRefGoogle Scholar
  48. 48.
    Böhm M, Luger TA, Bonsmann G. Disseminated superficial actinic porokeratosis: treatment with topical tacalcitol. J Am Acad Dermatol. 1999;40:479–80.PubMedCrossRefGoogle Scholar
  49. 49.
    Shelley WB, Shelley ED. Disseminated superficial porokeratosis: rapid therapeutic response to 5-fluorouracil. Cutis. 1983;32:139–40.PubMedGoogle Scholar
  50. 50.
    Schwartz T, Seiser A, Gschnait F. Disseminated superficial actinic keratosis. J Am Acad Dermatol. 1982;11:724–30.CrossRefGoogle Scholar
  51. 51.
    Nayeemuddin FA, Wong M, Yell J, Rhodes LE. Topical photodynamic therapy in disseminated superficial actinic porokeratosis. Clin Exp Dermatol. 2002;27:703–6.PubMedCrossRefGoogle Scholar
  52. 52.
    Cavicchini S, Tourlaki A. Successful treatment of disseminated superficial actinic porokeratosis with methyl aminolevulinate-photodynamic therapy. J Dermatolog Treat. 2006;17:190–1.PubMedCrossRefGoogle Scholar
  53. 53.
    Phillips RW, Wong RK. Barrett’s esophagus: natural history, incidence, etiology, and complications. Gastroenterol Clin North Am. 1991;20:791–816.PubMedGoogle Scholar
  54. 54.
    Reid BJ, Levine DS, Longton G, Blount PL, Rabinovitch PS. Predictors of progression to cancer in Barrett’s esophagus: baseline histology and flow cytometry identify low- and highrisk patient subsets. Am J Gastroenterol. 2000; 95:1669–76.PubMedGoogle Scholar
  55. 55.
    Montgomery E, Goldblum JR, Greenson JK, Haber MM, Lamps LW, Lauwers GY, Lazenby AJ, Lewin DN, Robert ME, Washington K, Zahurak ML, Hart J. Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study. Hum Pathol. 2001;32:379–88.PubMedCrossRefGoogle Scholar
  56. 56.
    Schnell TG, Sontag SJ, Chejfec C, Aranha G, Metz A, O’Connell S, Seidel UJ, Sonneberg A. Long-termnonsurgical management of Barrett’s esophagus with high-grade dysplasia. Gastroenterology. 2001;120:1607–19.PubMedCrossRefGoogle Scholar
  57. 57.
    Overholt BF, Panjehpour M, Haydek JM. Photo­dynamic therapy for Barrett’s esophagus: follow-up in 100 patients. Gastrointest Endosc. 1999;49:1–7.PubMedCrossRefGoogle Scholar
  58. 58.
    Overholt BF, Panjehpour M, Halberg DL. Photodynamic therapy for Barrett’s esophagus with dysplasia and/or early stage carcinoma: long-term results. Gastrointest Endosc. 2003;58:183–8.PubMedCrossRefGoogle Scholar
  59. 59.
    Regula J, MacRobert AJ, Gorchein A, Buonaccorsi GA, Thorpe SM, Spencer GM, Hatfield AR, Bown SG. Photosensitisation and photodynamic therapy of oesophageal, duodenal, and colorectal tumours using 5-aminolaevulinic acid induced protoporphyrin IX – a pilot study. Gut. 1995;36:67–75.PubMedCrossRefGoogle Scholar
  60. 60.
    Gary D. Mackenzie & Jason M. Dunn & C. R. Selvasekar & C. Alexander Mosse & Sally M. Thorpe & Marco R. Novelli & Stephen G. Bown & Laurence B. Lovat. Optimal conditions for successful ablation of high-grade dysplasia in Barrett’s oesophagus using aminolaevulinic acid photodynamic therapy. Lasers Med Sci. 2009;24:729–34.PubMedCrossRefGoogle Scholar
  61. 61.
    Kaufman SR. Developments in age-related macular degeneration: diagnosis and treatment. Geriatrics. 2009;64(3):16–9.PubMedGoogle Scholar
  62. 62.
    Bressler NM. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials – tap report 2. Arch Ophthalmol. 2001;119(2):198–207.PubMedGoogle Scholar
  63. 63.
    Potter MJ, Szabo SM. Verteporfin photodynamic therapy-induced apoptosis in choroidal neovascular membranes. Br J Ophthalmol. 2006;90:1034–9.CrossRefGoogle Scholar
  64. 64.
    Verteporfin Roundtable 2000 and 2001 Participants, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group, Verteporfin in Photodynamic Therapy (VIP) Study Group Principal Investigators. Guidelines for using verteporfin (visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. Retina. 2002;22(1):6–18.CrossRefGoogle Scholar
  65. 65.
    Spaide RF, Sorenson J, Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology. 2005;112(2):301–4.PubMedCrossRefGoogle Scholar
  66. 66.
    Lang GE, Mennel S, Spital G, Wachtlin J, Jurklies B, Heimann H, et al. Different indications of photodynamic therapy in ophthalmology. Klin Monatsbl Augenheilkd. 2009;226(9):725–39. Epub 2009 Jul 14 [Article in German].Google Scholar
  67. 67.
    Escudero A, Nagore E, Sevila A, Sanmartin O, Botella R, Guillenx C. Chronic-ray dermatitis treated by topical 5-aminolaevulinic acid – photodynamic therapy 2002 British Association of Dermatologists. Br J Dermatol. 2002;147:385–410.CrossRefGoogle Scholar
  68. 68.
    Lessana-Leibowitch M, Monsuez JJ, Noble JP, Sedel D, Cadot M, Hewitt J. Manifestations cutanees de la sarcoidose. Ann Med Interne (Paris). 1984;135:97–101.Google Scholar
  69. 69.
    Kerdel FA, Moschella SL. Sarcoidosis: an updated review. J Am Acad Dermatol. 1984;11:1–19.PubMedCrossRefGoogle Scholar
  70. 70.
    Karrer S, Abels C, Beatrix Wimmershoff M, Landthaler M, Szeimies RM. Successful treatment of cutaneous sarcoidosis using topical photodynamic therapy. Arch Dermatol. 2002;138:581–4.PubMedCrossRefGoogle Scholar
  71. 71.
    Goltz RW, Peterson WC, Gorlin RJ, Ravits HG. Focal dermal hypoplasia. Arch Dermatol. 1962;86:708–17.PubMedGoogle Scholar
  72. 72.
    Goltz RW. Focal dermal hypoplasia syndrome. An update. Arch Dermatol. 1992;128:1108–11.PubMedCrossRefGoogle Scholar
  73. 73.
    Mallipeddi R, Chaudhry SI, Darley CR, Kurwa HA. A case of focal dermal hypoplasia (Goltz) syndrome with exophytic granulation tissue treated by curettage and photodynamic therapy. Clin Exp Dermatol. 2006;31:228–31.PubMedCrossRefGoogle Scholar
  74. 74.
    Ufret-Vincenty RL, Miller JW, Gragoudas ES. Photosensitizers in photodynamic therapy of choroidal neovascularization. Int Ophthalmol Clin. 2004;44:63–80.PubMedCrossRefGoogle Scholar
  75. 75.
    Perez MI, Kohn SR. Cutaneous manifestations of diabetes. J Am Acad Dermatol. 1994;30:519–31.PubMedCrossRefGoogle Scholar
  76. 76.
    Meurer M, Szeimies RM. Diabetes mellitus and skin diseases. Curr Probl Dermatol. 1991;20:11–23.PubMedGoogle Scholar
  77. 77.
    Norman A. Dermal manifestations for diabetes. In: Norman R, editor. Geriatric dermatology. New York: Parthenon Publishing Group; 2001. p. 143–54.Google Scholar
  78. 78.
    Kreuter A, Knierim C, Stucker M, Pawlak F, Rotterdam S, Altmeyer P, Gambichler T. Fumaric acid esters in necrobiosis lipoidica: results of a prospective noncontrolled study. Br J Dermatol. 2005;153:802–7.PubMedCrossRefGoogle Scholar
  79. 79.
    De Rie MA, Sommer A, Hoekzema R, Neumann HA. Treatment of necrobiosis lipoidica with topical psoralen plus ultraviolet A. Br J Dermatol. 2002;147:743–7.PubMedCrossRefGoogle Scholar
  80. 80.
    Heidenheim M, Jemec GBE. Successful treatment of necrobiosis lipoidica diabeticorum with photodynamic therapy. Arch Dermatol. 2006;142:1548–50.PubMedCrossRefGoogle Scholar
  81. 81.
    Babilas P, Karrer S, Sidoroff A, Landthaler M, Szeimeies RM. Photodynamic therapy in dermatology: an update. Photodermatol Photoimmunol Photomed. 2005;21:142–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Dermatology and Laser Center of MauiKiheiUSA

Personalised recommendations